Bernstein lowered the firm’s price target on Revvity (RVTY) to $120 from $140 and keeps a Market Perform rating on the shares. With tariffs, concerns about NIH and broader academic/government funding, and HHS hits to pharma that have already come and that may still be in the works, the firm believes the recovery in tools isn’t happening the way it hoped it would at the beginning of the year. Measures of the health sector show that these theoretical risks are actually playing out in the numbers, and Bernstein heads into Q1 cautious.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target lowered to $116 from $143 at BofA
- Revvity price target lowered to $110 from $140 at Barclays
- Revvity announces FDA approval for Auto-Pure 2400 liquid handling platform
- Revvity enters agreement with Genomics England for Generation Study collab
- Revvity wins permanent injuction to enforce agreements with Cloud Software Group